Trial reportScientific reports2018
High prevalence of hepatitis delta virus in Cameroon.
Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis.JMIR public health and surveillance · 2022Pooled it
- Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis.PLoS medicine · 2020Pooled it
- Prevalence and biomarker profiles of HBV/HDV coinfection and occult HBV infection among patients attending Bimbilla Hospital, Northern Ghana.BMC infectious diseases · 2026Article
- Article
- High Prevalence of Active HDV Infection Among HBsAg-Positive Patients in Urban and Rural Areas in Gabon: A Cross-Sectional Retrospective Study.Health science reports · 2026Article
- Viral hepatitis as a differential diagnosis of yellow fever suspected cases in Cameroon: Prevalence and molecular characterization.IJID regions · 2025Article
- Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: A multi-country survey.JHEP reports : innovation in hepatology · 2025Article
- Prevalence and risk factors of transmission of hepatitis delta virus in pregnant women in the Center Region of Cameroon.PloS one · 2024Article
- High prevalence of hepatitis delta virus among people with hepatitis B virus and HIV coinfection in Botswana.Journal of infection and public health · 2023Article
- Article
- The Abbott Pandemic Defense Coalition: a unique multisector approach adds to global pandemic preparedness efforts.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Endemicity and genetic diversity of Hepatitis delta virus among Pygmies in Cameroon, Central Africa.BMC research notes · 2022Article
- Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses.PloS one · 2020Article
- Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.PloS one · 2020Article
- Evolutionary trends in the prevalence of anti-HDV antibodies among patients positive for HBsAg referred to a national laboratory in Cameroon from 2012 to 2017.BMC research notes · 2019Article
- A review on hepatitis D: From virology to new therapies.Journal of advanced research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis delta virus (HDV), a satellite virus of hepatitis B virus (HBV), infects an estimated 15-20 million people worldwide and confers a greater risk for accelerated progression to liver disease. However, limited HDV surveillance data are available in sub-Saharan Africa where HDV diversity is high. To determine the prevalence and diversity of HDV in Cameroon, serological and molecular characterization was performed on 1928 HBsAg positive specimens selected from retrospective viral surveillance studies conducted in Cameroon from 2010-2016. Samples were screened for HDV antibodies on the Abbott ARCHITECT instrument and for HDV RNA on the Abbott m2000 instrument by research assays. HDV positive specimens with sufficient viral load were selected for genomic sequencing. The seroprevalence of HDV in HBsAg positive samples from Cameroon was 46.73% [95% CI; 44.51-48.96%], with prevalence of active HDV infection being 34.2% [95% CI; 32.09-36.41%]. HDV genotypes 1, 6, 7 and 8 were identified amongst N = 211 sequences, including N = 145 genomes. HDV prevalence is high within the study cohort, indicating that a large portion of HBV infected individuals in Cameroon are at elevated risk for severe hepatitis and death. Collectively, these results emphasize the need for HBV vaccination and HDV testing in HBsAg positive patients in Cameroon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.